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ABSTRACT
Objectives: With the growing number of new breast cancer cases in women, new methods of imaging arise. Contrast 
enhanced spectral mammography (CESM) and magnetic resonance imaging (MRI) are comparable methods regarding 
sensitivity. The aim of this study is to check if analysis of background parenchymal enhancement on CESM can improve 
its usefulness.
Material and methods: A total of 64 patients with breast lesions found previously on ultrasound or mammography 
underwent MRI and CESM within less than one month. On MRI the contrast enhancement kinetics and visual BPE were 
evaluated. On CESM the enhancement of lesions was noted as well as a quantitative level of BPH. The gathered data was 
analysed in terms of patterns and relations.
Results: A total of 66 lesions were identified both on MRI and CESM, including 11 (17%) benign and 55 (83%) malignant 
lesions. Among malignant lesions 13 (20%) were assessed as intraductal and 42 (64%) as infiltrating carcinomas. The study 
showed correlation between the level of enhancement on CESM and the type of kinetic curve on MRI and lesion enhance-
ment on CESM as well as confirmed the fact that the BPE is a destimulant in both methods of imaging.
Conclusions: Evaluation of BPE level on CESM can help reading radiologists to define a lesion as malignant with higher 
probability than based only on the qualitative lesion enhancement level.
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INTRODUCTION
Nowadays, breast cancer is the most frequent type of 
cancer in women in the European Union countries (29.2% 
of all cancers) [1]. Early detection of cancer significantly 
increases the chance for cure [2]. Therefore, at the time of 
fast developing technology, basic imaging methods such as 
ultrasonography and mammography were complemented 
by MRI (magnetic resonance imaging) and more recently 
by CESM (contrast enhanced spectral mammography), ac-
cepted by FDA in 2011.
Both methods are stated to have comparable sensitiv-
ity and specificity described in numerous studies, which 
enables more diagnostic possibilities in a bigger number of 
patients. Above examinations can be applied interchange-
ably in cases when the patients report contraindications to 
any of them [3–5]. This fact emphasises the need of exploring 
all the aspects of every new method, including CESM.
Breast parenchymal enhancement (BPE) is a feature 
routinely evaluated on MRI [6]. MRI reports include one 
of four BPE values measured qualitatively: minimal, mild, 
moderate, marked and symmetry of enhancement in both 
breasts. A correlation between BPE on MRI and breast can-
cer risk was found. The stronger the enhancement, the 
higher the risk [7]. What is more, lesion evaluation on the 
background of strongly marked BPE is much more difficult 
for a radiologist describing the findings. 
Similarity of this imaging method to CESM leads to the 
assumption that this parameter should be also measurable 
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on CESM. So far, the studies analysed BPE only in terms of 
finding if its value can determine the risk of breast cancer 
[8, 9]. The outcomes of these analyses indicate that the 
parameter should be taken into consideration in the final 
assessment of examination. Up to now BPE on CESM has not 
been compared to BPE on MRI in the same patients. The aim 
of our study is to determine the usefulness of BPE evaluation 
on CESM. We also checked if it allows radiologists to assess 
lesions and exclude the probability of neoplastic process 
with greater certainty. 
This study was performed in compliance with the Decla-
ration of Helsinki and it received the approval of the Ethical 
Committee at the Regional Medical Chamber (acceptance 
No. OIL/KBL/17/2018).
MATERIAL AND METHODS
Both examinations, CESM and MRI were performed 
on 84 patients in 2018. Patients suspicious of multifocality 
and multicentricity or in case of other diagnostic doubts 
such as heterogeneous or dense breast anatomy under-
went CESM examination. MRI examination followed CESM 
if the diagnostic problem was still present or if histopatho-
logic verification was necessary for lesions visible only after 
contrast administration. Within the observed group the 
enhancement visible on CESM was not confirmed on MRI 
in 5 cases. Another 6 patients were referred to chemotherapy 
due to extension of the disease process and receptor status 
and 7 patients underwent surgical procedure in another On-
cology Clinic. As a result, the analysis comprises 64 patients 
who underwent breast CESM and MRI.
For CESM a protocol routinely used in the department 
was applied with GE Senographe Essential machine. Con-
trast medium administration was performed with an au-
tomatic syringe Optivantage DH. Dose of contrast media 
(iopromide a 370 mg/mL) was calculated following the for-
mula 1.5 mL/kg of body weight. Patients without any known 
contradictions were given a bolus of contrast with a rate of 
3 mL/s followed by a chaser of NaCl 0.9% solution. At that 
moment, a timer was started and after 2 minutes the first 
image acquisition was performed. A total of 4 exposures 
were performed in the following order: craniocaudal (CC) 
of the breast with smaller probability of cancer based on 
preliminary diagnostic imaging, CC of the more suspicious 
breast, mediolateral oblique (MLO) of first breast and then 
MLO of the second breast. 
Lesion enhancement was evaluated on subtraction im-
ages and described qualitatively as weak, medium or strong 
as well as qualitatively using the Region of Interest (ROI) tool. 
Figure 1. Measurement of BPE value and lesion enhancement using an ellipse shaped Region of Interest (ROI) on contrast enhanced spectral 
mammography (CESM) from Figure 2
Figure 2. Relation between qualitative lesion enhancement 
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ROI is a part of the used SenoIris software and gives informa-
tion of the minimum, maximum and average pixel bright-
ness distribution within the shape of our choosing (oval 
was used in this study). Since there are only 2 time-points of 
contrast kinetics measured, there is no possibility to assess 
a kinetic curve like in breast MRI.
BPE on CESM was measured with the ROI with an oval 
shape in the most homogenous part of parenchyma both in 
CC and MLO views of the breast with the suspicious lesion 
(Fig. 1). Afterwards, the values were divided into 4 equal 
ranges and described as minimal, mild, moderate and 
marked to adapt the scale to the one used in MRI (ACR 
BI-RADS standards for reporting). 
In order to compare BPE on CESM and MRI qualitative 
assessment was performed based on enhancement values 
measured with ROI. For every patient mean BPE was calcu-
lated for CC and MLO views. The obtained results ranged 
from 2000.7 to 2067.1. As a next step, the enhancement 
values were divided into four scopes, following the BI-RADS 
standards for BPE evaluation on MRI: minimal ranging from 
2000.7–2017.3, mild — 2017.4–2033.9, moderate — 2034.0– 
–2050.5, marked — 2050.6–2067.1.
MRI examination was performed using Siemens Avan-
to 1,5T machine. Patients without any known contradic-
tions were qualified for the examination. There was a strict 
time requirement of menstrual cycle for the patients to be 
scheduled for the examination – the day of the procedure 
was within 5–12 day of the cycle. If the patient underwent 
hysterectomy, they had their progesterone level evaluated 
before the exam. Only patients with the progesterone level 
within follicular phase of the menstrual cycle were qualified 
for the study. The protocol used included T1WI, T2WI — with 
and without Fat Suppression (FATSAT), Diffusion Weighted 
Images (DWI), and dynamic T1-weighted 3D sequence after 
contrast media administration. Contrast medium (gadobu-
trolum a 0.60472 g/mL) was injected using Optistar Elite 
automatic syringe. The amount of contrast was calculated 
according to 0.1 mL/kg of body weight formula. 
Lesion kinetic curve assessment was performed after-
wards using Siemens syngo® software and described as 
persistent, plateau or wash-out.
Histopathological examination
All lesions were histopathologically verified. Following bi-
opsy, methods were used to obtain lesion samples: core-nee-
dle biopsy, vacuum assisted breast biopsy, stereotactic biopsy 
guided on MG/MRI or lumpectomy. Standard hematoxylin 
and eosin staining was followed by histopathological ex-
amination by pathologists experienced in breast diseases.
Histopathological examination confirmed the presence 
of one focal lesion in all 66 patients on both CESM and MRI. 
Among all diagnosed lesions 55 (83%) were malignant in-
cluding 42 (64%) infiltrating lesions, and 13 (20%) non-infil-
trating lesions. The remaining 11 (17%) lesions were benign.
Statistical methods
Statistica software and following statistical methods 
were used for calculations:
•	 chi-squared dependence test to compare lesion en-
hancement on CESM and its histopathological character; 
BPE parameter assessment both on CESM and MRI in 
terms of its histopathological type; assess the influence 
of BPE on MRI on enhancement curve type on MRI
•	 ROC analysis to check if quantitative lesion enhance-
ment on CESM and lesion enhancement curve type on 
MRI depends on histologically determined cancer stage 
•	 Kruskal-Wallis test ANOVA to assess the relation between 
ratio of quantitative BPE value on CESM to quantita-
tive lesion CESM enhancement and qualitative lesion 
enhancement on CESM; assess the relation between 
qualitative BPE on CESM and BPE on MRI; compare the 
quantitative BP enhancement indicator on CESM and 
quantitative lesion enhancement on CESM to BPE on MRI
•	 Mann-Whitney U test to compare the quantitative BP 
enhancement indicator on CESM and quantitative le-
sion enhancement on CESM to lesion enhancement 
curve on MRI
RESULTS
CESM qualitative enhancement of the lesion 
Based on CESM results, weak enhancement was de-
termined for 12 (18%) lesions, medium for 21 (32%), and 
strong for 33 (50%). Strong enhancement was more frequent 
among malignant lesions than benign (56% vs 18%). This 
relation was statistically significant (proportion test p=0.02). 
However, the number of benign cases classified with strong 
enhancement was only two. The relation between lesion 
type (malignant and benign) and enhancement level was 
not statistically significant (chi-squared dependence test 
p = 0.054).
Lesion enhancement level depends on lesion type only 
if the classification of the lesions is extremely specific, i.e. 
infiltrating and non-infiltrating benign lesions (chi-squared 
dependence test p = 0.0006). The higher the level of malig-
nancy, the more often the enhancement visible on CESM 
was described as strong. Consequently, the more benign the 
lesion was, the more often the enhancement was described 
as weak on CESM. This is shown in Figure 2.
There was also a significant difference between me-
dian value of quantitative lesion enhancement on CESM and 
histopathological result (U Manna-Whitney test p = 0.03) 
and lesion type (Kruskal-Wallis test p = 0.05). Figure 3 shows 
that there has been a gradual increase in the median value 
of lesion enhancement on CESM with rising the degree of 
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malignancy of the lesion. Therefore, the result for compari-
son of qualitative and quantitative lesion enhancement on 
CESM with lesion type is comparable. 
As a next step quantitative BPE value on CESM was 
compared. In the analysed material, median value of BPE 
on CESM was 2030.11 — minimum 2000.7, maximum 
2067.1. BPE value was neither related to the type of lesion 
nor to its malignancy as shown in Figure 4A and 4B.
The enhancement values on CESM were analysed with 
ROC to determine whether the lesions could be described as 
malignant on their basis and what range of values would be 
adequate. Based on quantitative and qualitative enhance-
ment it was possible to determine the lesion’s malignancy 
(p < 0.01 AUC). The malignancy can be determined based 
on percentage ratio of BPE value on CESM to lesion CESM 
enhancement (p = 0.0004). The described ratio/indicator 
is incredibly useful in differentiating between benign and 
malignant lesions — AUC [(area under curve) is the biggest, 
p is the lowest and the estimated sensitivity, specificity 
and accuracy based on threshold value are the highest. 
This ratio/indicator is a distimulant, which means that the 
lower its value, the higher the malignancy of the lesion. 
The results of analysis showed that for values smaller or 
equal 97.3% lesions can be described as malignant. All val-
ues are shown in Table 1.
The results show that the variable is a destimulant, which 
means that the lower its value, the higher the malignancy 
of the lesion. Further step involved determining whether 
quantitative lesion enhancement value on CESM depends 
on qualitative BPE on CESM. This relation is presented in 
Figure 5. 
Figure 3. Relation between qualitative lesion enhancement 

















































Figure 4. Relation between mean quantitative background parenchymal enhancement (BPE) value on contrast enhanced spectral mammography 










































































Table 1. AUC, p and threshold values for calculation of lesion 
enhancement and BPE
Parameter on CESM AUC p Treshold value
Qualitative lesion 
enhancement 0.711 0.0110 Strong
Quantitive lesion 
enhancement 0.712 0.0077 2091.5
BPE quantitive* 0.582 0.3398 2018.86
BPE qualitive* 0.569 0.4191 minimum
Ratio/indicator* 0.746 0.0004 97.3
* destimulant; AUC — area under curve; CESM — contrast enhanced spectral 
mammography; BPE — background parenchymal enhancement
96
Ginekologia Polska 2021, vol. 92, no. 2
www. journals.viamedica.pl/ginekologia_polska
There is a strong correlation between BPE qualitative 
enhancement on CESM and lesion qualitative enhancement 
on CESM ratio and qualitative enhancement (Kruskal Wal-
lis test ANOVA p < 0.001). The smaller the share - the ratio 
value — the stronger enhancement on CESM. Additionally, 
the rank correlation between mean enhancement on CESM 
and mean BPE enhancement was evaluated (p = 0.01). Cor-
relation coefficient was 0.31.
MRI qualitative BPE and lesion enhancement 
BPE was determined as minimum on MRI in 16 (24%) cases, 
mild in 33 (50%) cases, moderate in 13 (19%) cases and marked 
in 4 (6%) cases. Both BPE on CESM and BPE on MRI do not reveal 
malignancy of the detected lesion neither imply the particu-
lar type of lesion (chi-squared dependence test p = 0.93 and 
0.99 respectively). Taking p into account, enhancement and 
lesion type are not related to parenchymal enhancement.
It was analysed to which extent curve type on MRI 
and level of BP enhancement could be applied to determine 
lesion malignancy. Based on the curve type on MRI it is 
possible to decide if the lesion is malignant (ROC analysis 
p < 0.001), i.e. reference level type III (wash-out). Parenchy-
mal enhancement level on MRI, similarly to BPE on CESM 
does not allow to determine malignancy (p = 0.69). This 
variable is also destimulant. This is shown in Table 2.
Material analysis revealed a lack of correlation between 
curve type on MRI and BPE on MRI (chi-squared dependence 
test p = 0.68). Type II of kinetic curve in lesion was seen in 
patients with PBE on MR described as: minimal in 31%, mild 
in 50%, moderate in 15%, marked in 4% of total cases. Type 
III was seen in lesion with BPE described as: minimal in 20%, 
mild in 50% moderate in 23%, marked in 7% of cases.
It was also proved that mean qualitative BPE on CESM is 
not related to BPE level on MRI (Kruskal Wallis test ANOVA 
p =  0.06). Figure 6 shows the values.
Comparison of BPE on CESM to mean enhancement 
ratio with the results of MRI examination shows that the 
ratio depends on curve type on MRI (U Mann-Whitney test 
p = 0.0004). The ratio is lower for lesions with determined 
curve type III on MRI but is not related to BPE level on MRI 
(Kruskal-Wallis test ANOVA p = 0.63). Figure 7a and 7b show 
the relations.
The analysis also revealed a lack of relation between 
qualitative BPE on MRI and CESM. The assessments of both 
methods were concordant in only 20 cases (30%) — i.e. that 
many cases were evaluated the same on both methods of 
examination. It is worth noting, that none of the cases de-
termined as marked on CESM was determined as marked 
on MRI. The cases described as marked on MRI were char-
acterised by the lowest BPE value.
DISCUSSION
The study revealed that analysis of BPE on CESM brings 
tangible results. It appeared that this feature is a destimulant 
both on MRI and CESM. It can be said that it creates noise 
which deteriorates the visibility of lesions in breast imaging 
examinations. Therefore, the assessment of this parameter 
allows reading radiologists to determine breast cancer prob-
ability with greater accuracy.
Figure 5. Relation between mean quantitative background 
parenchymal enhancement (BPE) value on contrast enhanced spectral 





































Table 2. AUC parameter, p and threshold value for calculations of 
MRI kinetic curve and BPE in MRI
Parameter AUC p Treshold value
Qualitative 
enhancement 0.864 0.0000 Type III
Quantitative 
enhancement 0.538 0.6861 moderate
AUC — area under curve
Figure 6. Relation between mean quantitative background 
parenchymal enhancement (BPE) value on contrast enhanced 
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Our findings are not consistent with the results of previ-
ous study [10], where BPE did not affect lesion detection effi-
cacy on CESM. It is important to emphasise that in our study 
quantitative BP and lesions enhancement were evaluated for 
the first time, which could have influenced the discrepancy 
between the results. This issue requires further analysis.
Since mammography examination is two-dimensional, 
BPE is not reproduced on CESM in the same way as on MRI. 
That is the reason why quantitative assessment brings ad-
vantages and increases repeatability. 
As a limitation of our study we should mention a lack of 
data on the menstruation cycle day of the patients admitted 
for CESM and carefully selected date of MRI examination. 
However, it results from the studies [3, 11] that the menstrual 
cycle does not influence BPE on CESM significantly and it 
does not fluctuate during the cycle. Another limitation is 
a small group of analysed patients. It stems from a retro-
spective form of conducted analysis and limited number of 
patients who underwent both examinations due to clinical 
indications before treatment.
CONCLUSIONS
Our study suggests that evaluation of BPE level on CESM 
can help radiologists to define a lesion as malignant with 
higher probability than based only on the qualitative lesion 
enhancement level and should be evaluated for each patient.
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Figure 7. Relation between quantitative background parenchymal enhancement (BPE) value on contrast enhanced spectral mammography (CESM) 
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